Clio Asset Management
PVLA icon

Clio Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Clio Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.9M Sell
86,012
-331
-0.4% -$49.1K 9.97% 3
2026
Q2 		$13.2M Sell
86,343
-4,414
-5% -$536K 10.49% 2
2026
Q1 		$11.3M Sell
90,757
-885
-1% -$92.3K 9.48% 3
2025
Q4 		$9.6M Buy
91,642
+1
+0% +$85 7.45% 6
2025
Q3 		$5.74M Buy
91,641
+133
+0.1% +$5.93K 4.26% 11
2025
Q2 		$2.06M Buy
+91,508
New +$2.15M 1.62% 12

Other funds holding PVLA

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Nan Fung Trinity
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Lisanti Capital Growth
Lisanti Capital Growth New York $373M AUM 178.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
ACPLP
ACT Capital Partners, L.P. Wayne, Pennsylvania $154M AUM
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return

Clio Asset Management's PVLA Position: Q3 2026 in Review

Clio Asset Management reduced its Palvella Therapeutics (PVLA) stake by 0.38% in Q3 2026, selling an estimated $49.1K and leaving 86,012 shares worth $11.9M. The position accounts for 9.97% of the portfolio, ranked #3.

Clio Asset Management first reported a position in PVLA in Q2 2025 and has held it in 6 quarters since. The position peaked at $13.2M in Q2 2026. 67 funds tracked by Wall St. Rank hold PVLA as of Q3 2026.

  • Clio Asset Management held 86,012 shares of Palvella Therapeutics worth $11.9M as of Q3 2026.
  • Clio Asset Management sold 331 Palvella Therapeutics shares in Q3 2026, an estimated $49.1K.
  • Palvella Therapeutics made up 9.97% of Clio Asset Management's portfolio in Q3 2026, its #3 holding.
  • Clio Asset Management first reported a position in Palvella Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Clio Asset Management's Palvella Therapeutics position peaked at $13.2M in Q2 2026.
  • 67 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2026.

Based on Clio Asset Management's 13F filing for Q3 2026, filed 13 Oct 2026.